United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2016_register executive 2016-11-29 article Notices D09002ee1c7f32599 D09002ee1c7f32626 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency The National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Braeburn Pharmaceuticals, Inc. ("Braeburn") located in Princeton, New Jersey to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice. 81 FR 85982 https://www.govinfo.gov/app/details/FR-2016-11-29/2016-28698 2016-28698 fr29no16-72 4140-01-P https://www.govinfo.gov/app/details/FR-2016-11-29/2016-28698 https://www.govinfo.gov/content/pkg/FR-2016-11-29/html/2016-28698.htm https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/2016-28698.pdf 2 p. 85982 85983 81 FR 85982 Prospective Grant of Exclusive Patent License: Development and Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial Agonists for the Treatment of Opioid Use Disorder, Schizophrenia Bipolar Disorder and Tetrahydrocannabinol Dependence; Federal Register Vol. 81, Issue NOTICE 2016-28698 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2016-12-14 4140-01-P 2016-28698 Notice.

The National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Braeburn Pharmaceuticals, Inc. ("Braeburn") located in Princeton, New Jersey to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.

Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before December 14, 2016 will be considered. Prospective Grants of Exclusive Patent Licenses: Development and Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial Agonists for Treatment of Opioid Use Disorder, Schizophrenia Bipolar Disorder and Tetrahydrocannabinol Dependence , lubetm@mail.nih.gov Vol. 81, no. 229 Office of the Federal Register, National Archives and Records Administration 2016-11-29 continuing daily deposited born digital 425 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2016-11-29 P0b002ee192cb8a83 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr29no16 https://www.govinfo.gov/app/details/FR-2016-11-29 https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/FR-2016-11-29.pdf https://www.govinfo.gov/content/pkg/FR-2016-11-29/xml/FR-2016-11-29.xml fdlp 85837 86248 DGPO 2016-11-29 2024-06-01 FR-2016-11-29 machine generated eng FR FR-2016-11-29 81 229